Gilead Sciences’ Post

A new, powerful tool in the fight to end the HIV epidemic for everyone, everywhere

These preliminary results show that the various prevention methods offered by the Prevention Pilot Program have had significant success in reducing HIV transmission and infection. We have seen the effectiveness of the Prevention Pilot Program for a variety of populations, including gay men, bisexuals, heterosexuals, and adolescents. Our research team will continue to analyze this data in depth to further understand the actual effectiveness and applicability of various prevention methods. We hope that these findings will provide important reference and support for the development of more effective HIV prevention policies and measures. We also encourage all populations in need to actively participate in our prevention pilot program to help us work together to achieve the goal of zero new HIV infections. Let's work together to create a healthier, more equitable and inclusive society! #HIV Prevention #Interim Analysis #Research Results #Collaboration

Today marks an important milestone for women in HIV prevention research. In 2019, we met with a group of HIV physicians and community advocates in Rwanda to discuss how to collaborate on the conduct of a PrEP study that could potentially help meet the unique needs of cisgender women. That study would become PURPOSE 1. Fast forward to today, where we’re seeing the news of the initial findings from our PURPOSE program, the most comprehensive and diverse HIV prevention trial program ever conducted, guided by the pillars of partnerships, the voice of the people, person-centric design, and intentional commitment to diversity, equity, and inclusion. As a woman physician and scientist who has worked in the HIV field for decades, I’m blown away that our PURPOSE 1 trial is the first phase 3 HIV prevention trial ever to show ZERO infections for an investigational PrEP medication. Crucially, our trial participants were 5,300 cisgender women across 28 sites in sub-Saharan Africa, the population and region that sees the highest burden of new HIV diagnoses and who have historically been left out of pivotal clinical trials.  We were able to achieve these results thanks to the dedicated stakeholders who shared their unique perspectives and experiences to ensure we implemented a truly inclusive and effective trial, particularly the insights of our Global Community Accountability Group. I can’t fully express my gratitude for your invaluable contributions – we would not have gotten here without you. We look forward to presenting the full PURPOSE 1 findings later this year and continuing to work with so many members of the HIV community as we progress towards new options for PrEP. Together, we can help end the epidemic. #gileademployee #usonly #preventionwithpurpose Linda-Gail Bekker Flavia Matovu Kiweewa Heeran Makkan CAPRISA yvette raphael Ntando Yola Alex Kintu Christoph Carter Lillian Brown J. Carlo Hojilla Jenna Yager Sarah Puryear Larkin Callaghan

#PrEP medication and the lab testing required for its preventive benefits and insurance coverage are essential tools in ending the #HIV epidemic. As part of our commitment to improving #AccessForAll, we recognize the need to remove barriers to PrEP and PrEP screening. Discover how Labcorp's guideline-driven PrEP screening can help reduce financial barriers and support #HealthEquity: http://spr.ly/6046PVw8p

This year, on the 35th World AIDS Day, we mark the 20th anniversary of the United States President’s Emergency Plan for AIDS Relief (PEPFAR). The United States government’s theme for World AIDS Day 2023 is “World AIDS Day 35: Remember and Commit.” The theme is an opportunity to reflect on the progress we have collectively made with partners and to commit to the actions needed to end HIV/AIDS as a public health threat by 2030. Ambassador Nekengasong has shared that in a world before PEPFAR hospitals could only count the numbers of deaths, there was little hope for people with HIV. Today we remember those lives and commit to pushing forward with life saving treatment and prevention. PEPFAR is not only the most successful Global Public Health campaign ever launched, it is one of the finest displays of humanity the world has ever known. #WorldAidsDay #PEPFARproud #Remember #Commit

I engage in activities that contribute in many ways to the critical action to end of TB, HIV and Malaria by 2030. #EndTB #EndHIV #EndMalaria #EndPoverty #biodiversityconservation #Climatechangecountermeasures #genderequity

Learn the basics for prescribing and monitoring #PrEP and for incorporating PrEP services into your practices or local #HIV prevention programs by enrolling in “HIV PrEP: Prescribing PrEP:” https://lnkd.in/evPU5AnS

Decades of innovation in #HIV treatment has transformed the way patients live their lives. Now, a new digital assessment tool could assist further by helping uncover hidden burdens adversely impacting health-related quality of life. Learn more: https://gsk.to/44xcD9W #HIVScience

𝐏𝐄𝐏𝐅𝐀𝐑 𝐒𝐀𝐕𝐄𝐒 𝐋𝐈𝐕𝐄𝐒 These numbers represent hopes, dreams, and stories still being told. #PEPFAR has accomplished what was once deemed unattainable in the past two decades. Presently, nearly 20.5 million individuals are receiving crucial #HIV treatment, thanks to PEPFAR 🇺🇸. Explore the latest outcomes and future projections ⬇️ #WorldAIDSDay2023 Link to PEPFAR latest global results factsheet for December 2023: https://lnkd.in/duK9D6wV #USwithSA #PEPFAR #PEPFARinSA

For the upcoming #EuroTestWeek, taking place 20-27 May 2024, we remain committed to supporting efforts to ensure improved access to testing and care services for #HIV, #hepatits and #STIs. Let’s challenge and address stigma and discriminatory laws and policies to make testing available for all. To learn more about #EuroTestWeek, visit buff.ly/45ZstM5 #TestTreatPrevent